Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alx Oncology Holdings (ALXO) Total Current Liabilities (2019 - 2026)

Alx Oncology Holdings' Total Current Liabilities history spans 5 years, with the latest figure at $36.0 million for Q4 2023.

  • On a quarterly basis, Total Current Liabilities rose 27.1% to $36.0 million in Q4 2023 year-over-year; TTM through Dec 2023 was $36.0 million, a 27.1% increase, with the full-year FY2023 number at $36.0 million, up 27.1% from a year prior.
  • Total Current Liabilities hit $36.0 million in Q4 2023 for Alx Oncology Holdings, up from $35.1 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for ALXO hit a ceiling of $36.0 million in Q4 2023 and a floor of $5.0 million in Q4 2019.
  • Historically, Total Current Liabilities has averaged $17.8 million across 5 years, with a median of $15.3 million in 2021.
  • Biggest five-year swings in Total Current Liabilities: surged 146.53% in 2021 and later decreased 26.64% in 2023.
  • Tracing ALXO's Total Current Liabilities over 5 years: stood at $5.0 million in 2019, then increased by 24.48% to $6.2 million in 2020, then surged by 146.53% to $15.3 million in 2021, then skyrocketed by 85.19% to $28.3 million in 2022, then grew by 27.1% to $36.0 million in 2023.
  • Business Quant data shows Total Current Liabilities for ALXO at $36.0 million in Q4 2023, $35.1 million in Q3 2023, and $17.6 million in Q2 2023.